Rocket Lab reports record Q2 revenue above estimates as loss widens

Rocket Lab USA Inc (NASDAQ:RKLB) reported Q2 revenue of $234M, up 62% YoY and above estimates of about $231.6M to $232M. GAAP loss was $0.08 per share, worse than forecasts of $0.03 to $0.06. Net loss was $49.3M and free cash flow was -$110.1M. Q3 revenue guidance is $250M to $265M; backlog reached $2.36B.

Original reporting
Published Aug 11, 2026, 5:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 11, 2026, 5:38 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Rocket Lab reports record Q2 revenue above estimates as loss widens — source image
Decision brief

The 30-second read

$RKLBBullishMed
01

Why it matters

Traders can update expectations for near-term revenue growth and margin compression, while also repricing backlog quality and execution risk around Neutron milestones and integration of acquired businesses.

02

Market read

A fresh earnings and guidance package with backlog and contract wins, plus M&A and Neutron execution milestones, drives a tradable repricing of growth versus margin/cash burn risk.

03

What to watch

Q3 gross margin guidance (29%-31% GAAP) is well below Q2 (36.1%), so investors may focus more on margin trajectory than backlog growth.

Relevance 8/10Novelty 8/10Timing: after-hours/earnings release day (shares down ~2% at $79)

Background

Rocket Lab is investing in Neutron while scaling Electron and space systems; the quarter also includes acquisition activity (Iridium planned, Mynaric and Motiv completed) and new contract awards.

Company-level read

Ticker impact

$RKLBBullishMedium confidence
Context

Rocket Lab reported record Q2 revenue of $234M above estimates, but widened GAAP loss to $0.08/share and guided Q3 revenue $250M-$265M.

Expected impact

Near-term bias modestly positive, but likely choppy given gross margin guidance below Q2 and negative free cash flow.

Evidence & confidence

The article provides fresh, decision-relevant numbers: Q2 beat, Q3 revenue range, gross margin ranges, backlog growth to $2.36B, and new launch contract wins plus M&A updates.

Market effects

Reinforces demand momentum in commercial space launch and space systems, but highlights margin volatility tied to Neutron investment.

Limited; primarily US-listed small/mid-cap space sector sentiment.

Moderate for defense and space procurement read-through via U.S. Space Force SB-AMTI contract awards.

Counterpoint

The revenue beat may not translate into improving profitability, since GAAP loss widened and free cash flow was deeply negative, suggesting dilution or funding risk.

Key entities

  • Rocket Lab USA Inc

    Reported record Q2 revenue above estimates, widened GAAP loss, provided Q3 revenue and gross margin guidance, and highlighted backlog and new contracts.

  • Iridium Communications

    Rocket Lab highlighted its planned acquisition of Iridium Communications.

  • U.S. Space Force

    Awarded Rocket Lab a $397.2M contract for multiple Flatellite spacecraft under SB-AMTI.

Related articles

$RKLBMed

Rocket Lab Falls 7% as Neutron Launch Window Narrows

Rocket Lab Corp. (RKLB) fell about 7% in extended trading after management said the first Neutron rocket flight may slip beyond 2026. The company now targets Neutron to reach the launch pad in Q4, with a year-end window narrowing. It expects Q3 gross margin of 29% to 31% versus a 37.6% estimate, despite Q2 revenue rising 62% to $234 million.

$RKLBMedAI 8/10

Rocket Lab Stock Tumbles After Q2 Earnings Misses Estimate

Rocket Lab (RKLB) shares fell about 2% after Q2 results. The company reported revenue of $234M, up 62% year over year and slightly above estimates, but an adjusted loss of 8 cents per share was worse than expected. Q3 GAAP gross margin guidance was 29% to 31%, below consensus. Investors also weighed margin pressure from satellite platform mix and questions about Rocket Lab’s planned $8B Iridium acquisition.

$RKLBMed

Rocket Lab’s $2.36 Billion Backlog Says the Neutron Delay Doesn’t Matter — Here’s Why

Rocket Lab (NASDAQ:RKLB) reported record Q2 revenue of $234 million, up 62% year over year, and said its backlog rose to $2.36 billion after securing over $1 billion in Q2 new awards. CEO Peter Beck cited a narrowing Neutron launch window. The company also expects a pending Iridium (NASDAQ:IRDM) deal adding about $870 million in annual revenue; analysts raised a price target to $122 from $96.

$RKLBMedAI 8/10

Rocket Lab Q2 2026 earnings: revenue up 62%, loss widens

Rocket Lab reported Q2 2026 revenue of $234 million, up 62% year over year, but a wider net loss of $49.3 million, or 8 cents per share, versus $66.4 million a year earlier. FactSet forecasts cited by The Wall Street Journal expected a 6-cent loss. Revenue mix rose in product sales to $181.3 million. Backlog was $2.36 billion. Q3 revenue guidance was $250-$265 million.

$RIOTHighAI 8/10

Riot, NIQ surge, On Holding tumbles premarket

U.S. stock futures were mostly flat as investors weighed geopolitical uncertainty and awaited U.S. inflation data. In premarket earnings moves, Riot Platforms rose on a $9.1B AI data center contract with Anthropic, NIQ Global Intelligence beat and raised guidance, On Holding fell on weaker sales, and Rocket Lab dropped on margin guidance.